Show simple item record

dc.contributor.authorLivi, L
dc.contributor.authorShah, N
dc.contributor.authorPaiar, F
dc.contributor.authorFisher, C
dc.contributor.authorJudson, I
dc.contributor.authorMoskovic, E
dc.contributor.authorThomas, M
dc.contributor.authorHarmer, C
dc.date.accessioned2018-06-26T08:38:15Z
dc.date.issued2003-01-01
dc.identifierhttp://publications.icr.ac.uk/1231/
dc.identifier.citationSARCOMA, 2003, 7 (3?4), pp. 149 - 152
dc.identifier.issn1357-714X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1923
dc.description.abstract<jats:p><jats:italic>Purpose:</jats:italic> The aim of this study was to assess treatment and outcome with respect to clinical and pathological features.</jats:p><jats:p><jats:italic>Patients and methods:</jats:italic> Thirty‐nine patients were identified (range 7–66 years, mean 23). Initial treatment comprised local excision in 11 patients and wide excision in 14. Post‐operative external beam radiotherapy was prescribed in 22 patients with a total dose of 60 Gy, delivered in two phases.</jats:p><jats:p><jats:italic>Results:</jats:italic> The cause‐specific survival for the entire group was 79, 63, 56 and 45% at 1, 3, 5 and 10 years, respectively. A distal limb location was associated with a better prognosis than proximal limb location (<jats:italic>P</jats:italic> = 0.04).</jats:p><jats:p><jats:italic>Conclusions:</jats:italic> Our data favour treatment with wide functional excision followed by radical dose radiotherapy in attempt to minimize risk of local recurrence, especially when primary tumours are bigger than 3 cm. Our data also suggest the same treatment for local recurrence, when technically possible, to avoid amputation.</jats:p>
dc.format.extent149 - 152
dc.languageeng
dc.language.isoeng
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleTreatment of Epithelioid Sarcoma at the Royal Marsden Hospital
dc.typeJournal Article
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2003
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSARCOMA
pubs.issue3?4
pubs.notespublic
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.volume7
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trials
dc.contributor.icrauthorJudson, Ian


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0